65,437 trials
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved at Least 20 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 20) at Week 16…
Waldenstrom's Macroglobulinemia
Primary: Number of Participants With Adverse Events — 4 Participants
Seborrheic Keratosis
Primary: Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale — 19; 0 Participants
Hepatitis C
Primary: Percentage of Participants Achieving SVR12 (Sustained Virologic Response 12 Weeks After the End of All Study Therapy) — 91.3; 100.0; 100.0; 100.0 Percentage of…
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Diabetic Foot Ulcers
Primary: Incidence of Complete Ulcer Closure Closure. — 1; 1; 3; 2 Participants — p=0.007
Inherited Mitochondrial Disease, Including Leigh Syndrome
Primary: Change From Baseline in Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Sections I-IV — -0.3; 0.1; -0.6; 0.0 units on a scale — p=0.1875
Advanced Breast Cancer · Breast Cancer
Primary: Progression Free Survival — 4.53; 6.83 months — p=0.231
Carcinoma, Renal Cell
Primary: Relative Tumor Size Change Following 8 Weeks of Therapy. — 1.4; -0.57 Percent change from baseline — p=0.69
Vascular Access Complications
Primary: First Attempt Success Rate With Peripheral IV (PIV) Catheter Placement — 84; 90 Participants
Hypertension
Primary: 24-hour BP (Systolic) — 113; 129 mmHg
Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicities — 0; 2; 2; 0 Participants
Esophageal Cancer · Gastric Cancer · Stomach Cancer
Primary: 7-month Progression-Free Survival — 0.581; 0.582 probability
Breast Cancer
Primary: Disease Progression — 1; 0 Participants
Heart Disease
Primary: Pulmonary Vascular Resistance — 153.8; 213.0; 174.6; 123.5 dyne*second/centimeter˄5 — p=<0.05